A vaccine developed by US-based Pfizer and Germany's BioNTech has shown 90% efficacy in trials, but pharma giant says the number may vary with further trials.
Berlin gave the German company $445 million in an agreement in September to help accelerate the vaccine by building out manufacturing & development capacity in its home market.
Pfizer and BioNTech announced Monday that their vaccine candidate prevented over 90% of Covid-19 cases in an early look at results from their 44,000-person clinical trial.
With effectiveness for first vaccines previously expected to be in range of 60% to 70%, more than 90% for Pfizer’s Covid vaccine is seen as extraordinary.
Pfizer and BioNTech on track to potentially be the first to show the efficacy of a Covid-19 vaccine, in an environment of intense scrutiny over every possible complication.
A little patience would help deliver much more information and give other vaccine hopefuls, apart from the front-runners, a chance to prove their worth as well.
Pfizer chief Albert Bourla says his firm and its partner BioNTech have a 60% chance of knowing the efficacy of their still experimental vaccine by end of October.
The view that bureaucracies are bloated with far too many employees preying on taxpayers money is a widely held myth. Research shows how significantly understaffed the Indian state is.
The Centre is considering an increase in the National Company Law Tribunal's bench capacity, while the Standing Committee of Finance suggests fast-track courts.
The helicopters produced by Lockheed Martin are known as ‘submarine hunters’. India ordered 24 of these aircraft in 2020 to replace the Sea King helicopters. 15 have been delivered till date.
The India-South Africa series-defining fact is the catastrophic decline of Indian red ball cricket where a visiting team can mock us with the 'grovel' word.
COMMENTS